Jessica Witter
Acute Care · Davenport, IANPI 1720265366
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Axonics, Inc. at 48.2% of the total. Reporting peaked in 2024 at $3,201 and has fallen 86.4% since, to $435 in 2025. Among acute care clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$3K
- Sumitomo Pharma America, Inc.$877
- Valencia Technologies Corporation$581
- Astellas Pharma US Inc$385
- Urovant Sciences Inc$251
- Antares Pharma, Inc.$125
- plus $585 from 11 others
What the payments were for
- Speaking & faculty fees$311%
- Travel & lodging$2,15940%
- Food & beverage$2,78151%
- Education$4458%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 29 | $2,613 |
| Sumitomo Pharma America, Inc. | 71 | $877 |
| Valencia Technologies Corporation | 11 | $581 |
| Astellas Pharma US Inc | 11 | $385 |
| Urovant Sciences Inc | 17 | $251 |
| Antares Pharma, Inc. | 1 | $125 |
| Teleflex LLC | 2 | $115 |
| Boston Scientific | 4 | $97 |
| Johnson & Johnson | 1 | $85 |
| Progenics Pharmaceuticals, Inc. | 2 | $84 |
| Seagen Inc. | 1 | $55 |
| Novartis | 2 | $44 |
| Pfizer | 2 | $33 |
| Abiomed | 1 | $26 |
| Medtronic | 1 | $17 |
| Merck | 1 | $15 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,416 in reported general payments places this provider in the 95th percentile of 104 acute care providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 768 | $520,586 |
| GemtesaVibegron | 384 | $254,015 |
| OrgovyxRelugolix | 39 | $105,425 |
| Tamsulosin Hcl | 886 | $15,320 |
| Mirabegron ErMirabegron | 32 | $14,280 |
| Solifenacin Succinate | 244 | $11,164 |
| Tolterodine Tartrate ErTolterodine Tartrate | 70 | $7,173 |
| Oxybutynin Chloride ErOxybutynin Chloride | 371 | $5,984 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 45 | $5,092 |
| Finasteride | 405 | $4,842 |
| Trospium Chloride | 67 | $4,486 |
| Silodosin | 30 | $3,690 |
| Estradiol | 56 | $3,482 |
| Trimethoprim | 51 | $3,255 |
| Tolterodine Tartrate | 40 | $3,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $385 | $520,586768 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $877 | $359,440423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 acute care providers in Iowa.
Other acute care in Davenport
- Teri DevineDavenport$4K
- Shawna DuskeDavenport$2K
- Heather HitesmanDavenport$2K
- Cheryl EhrlerDavenport$2K
- Gina ZelleDavenport$1K
- Cynthia BurkholderDavenport$1K
- Michelle LakeDavenport$1K
- Lori SchwarmDavenport$1K
- Abby ShumateDavenport$809
- Emily MaiersDavenport$627
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.